降压治疗与不良心血管结局:ICAPS全基因组交互作用荟萃分析
该研究基于国际抗高血压药物基因组学研究联盟(ICAPS)四项随机对照试验,对欧洲裔高血压患者进行全基因组药物-SNP交互作用荟萃分析,覆盖β受体阻滞剂、钙通道阻滞剂、噻嗪类利尿剂及ACEI/ARB四类降压药与心血管结局。β受体阻滞剂交互分析中rs139945292达全基因组显著性,T等位基因与收缩压和舒张压降压反应减弱及不良心血管风险增加相关。
要点
- rs139945292与β受体阻滞剂降压反应减弱及不良心血管风险增加相关。
- 该位点为NTM基因上游50kb的表达数量性状位点。
- 其他降压药物类别未发现达全基因组显著性的SNP。
核心结论
- NTM区域与β受体阻滞剂治疗患者不良心血管结局风险增加及血压降低幅度减小相关。
研究设计与样本
- 基于ICAPS四项随机对照试验,对欧洲裔高血压患者进行全基因组药物-SNP交互作用荟萃分析。
- β受体阻滞剂分析n=9,195,钙通道阻滞剂n=10,511,噻嗪/噻嗪样利尿剂n=3,516,ACEI/ARB n=2,559。
- 顶级SNP在CHARGE研究(n=21,267)中复制心血管结局,在独立ICAPS研究(n=1,552)中验证血压反应,在GenHAT非洲裔美国人(n=5,115)中进行种族验证。
主要发现
- β受体阻滞剂-SNP交互分析中rs139945292达全基因组显著性(交互P=1.56×10-8)。
- T等位基因与收缩压降压反应减弱相关(P=6×10-4,Beta=3.09),与舒张压降压反应减弱相关(P=5×10-3,Beta=1.53)。
- T等位基因在β受体阻滞剂治疗亚组中与不良心血管风险增加相关(P=2.35×10-4,OR=1.57,95%CI=1.23-1.99)。
- 该位点在CHARGE研究中获名义复制,在β受体阻滞剂治疗的非洲裔美国人中呈一致方向趋势。
- rs139945292为NTM(neurotrimin)基因上游50kb的表达数量性状位点。
局限性
- 其他降压药物类别未发现达全基因组显著性的SNP。
- 该区域需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We sought to identify genome-wide variants influencing antihypertensive drug response and adverse cardiovascular outcomes, utilizing data from four randomized controlled trials in the International Consortium for Antihypertensive Pharmacogenomics Studies (ICAPS). Genome-wide antihypertensive drug-single nucleotide polymorphism (SNP) interaction tests for four drug classes (β-blockers, n = 9,195; calcium channel blockers (CCBs), n = 10,511; thiazide/thiazide-like diuretics, n = 3,516; ACE-inhibitors/ARBs, n = 2,559) and cardiovascular outcomes (incident myocardial infarction, stroke, or death) were analyzed among patients with hypertension of European ancestry. Top SNPs from the meta-analyses were tested for replication of cardiovascular outcomes in an independent Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) study (n = 21,267), blood pressure (BP) response in independent ICAPS studies (n = 1,552), and ethnic validation in African Americans from the Genetics of Hypertension Associated Treatment study (GenHAT; n = 5,115). One signal reached genome-wide significance in the β-blocker-SNP interaction analysis (rs139945292, Interaction P = 1.56 × 10-8 ). rs139945292 was validated through BP response to β-blockers, with the T-allele associated with less BP reduction (systolic BP response P = 6 × 10-4 , Beta = 3.09, diastolic BP response P = 5 × 10-3 , Beta = 1.53). The T-allele was also associated with increased adverse cardiovascular risk within the β-blocker treated patients' subgroup (P = 2.35 × 10-4 , odds ratio = 1.57, 95% confidence interval = 1.23-1.99). The locus showed nominal replication in CHARGE, and consistent directional trends in β-blocker treated African Americans. rs139945292 is an expression quantitative trait locus for the 50 kb upstream gene NTM (neurotrimin). No SNPs attained genome-wide significance for any other drugs classes. Top SNPs were located near CALB1 (CCB), FLJ367777 (ACE-inhibitor), and CES5AP1 (thiazide). The NTM region is associated with increased risk for adverse cardiovascular outcomes and less BP reduction in β-blocker treated patients. Further investigation into this region is warranted.
引用
- McDonough CW, Warren HR, Jack JR, et al. Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies. Clin Pharmacol Ther. 2021. PMID: 34231218. doi:10.1002/cpt.2355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。